AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 31 min read$GKOS

WEN LEANA sold $88K of GKOS

WEN LEANA sold 525 shares of GLAUKOS Corp (GKOS) at $167.63 on 2026-07-31.

Original reporting
SEC EDGAR · WEN LEANA
Published Aug 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:17 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest fact is the reported open-market sale size, price, and post-transaction holdings for a director. It does not include any operational or financial guidance changes.

02

Market read

Traders may note insider selling for sentiment monitoring, but the disclosed value (~$88K) is unlikely to be a standalone catalyst.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says none), but it also provides no context on total holdings, prior sales cadence, or reasons for the transaction.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-03, transaction dated 2026-07-31.

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos Corp (GKOS).

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Glaukos director Wen Leana filed a Form 4 open-market sale of 525 shares at $167.63 on 2026-07-31, worth about $88K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying corporate news, guidance, or operational catalyst in the text.

Market effects

Sector

No sector read-through is provided beyond a routine insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or planned liquidity needs and may not signal reduced confidence.

Key entities

  • issuer
    GLAUKOS Corp

    Company whose director insider sale is disclosed via Form 4.

  • insider
    WEN LEANA

    Director reporting an open-market sale of 525 shares.

Read at source← All news

Related articles

AUG 8
$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min
JUL 30
$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

tradingview.com6 min
JUL 30
$GKOSMed

Glaukos Q2 Earnings Call Highlights

Glaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.

finance.yahoo.com4 min
JUL 29
$GKOSMedAI 8/10

GLAUKOS Corp (GKOS): Results of Operations and Financial Condition

GLAUKOS Corp (GKOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 JULY 29, 2026 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designe

SEC EDGAR 8-K6 min
JUL 29
$GKOSMed

Midday Stock Roundup: Glaukos Rises

A midday roundup highlights multiple movers. V.F. Corp. (VFC) fell 17% to $15.24 after lower first-quarter revenue tied to weakness in Vans and CFO Paul Vogel leaving. Envista (NVST) rose 6.2% to $28.63 ahead of an Sept. 17 investor day. Glaukos (GKOS) gained 7.9% to $159.25 after completing patient enrollment in a 510(k) glaucoma study.

ocbj.com3 min